drugset / Trial / NCT02299141
Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
20 enrolled
Washington University School of Medicine
National Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
There has been limited benefit with angiogenesis inhibitor drugs in molecularly unselected patients in non-small cell lung cancer (NSCLC). The investigators propose that patients who are molecularly selected for treatment with nintedanib based on the presence of mutations in the following genes: VEGFR1-3, PDGFR-A, PDGFR-B, FGFR1-3, and TP53, will have clinically meaningful benefit in terms of response rate (RR) and progression-free survival (PFS). Furthermore the investigators plan to correlate outcomes with specific mutations and evaluate mechanisms of resistance.
Timeline
- Start
- 2015-05-07
- Primary completion
- 2020-01-09
- Completion
- 2025-04-23
Publications
- Background Waqar SN, Rawat U, Morgensztern D, et al.; A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer (NSCLC) (NCT02299141). J. Clin. Oncol. 38:15_suppl, e21694-e21694; (2020) URL: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e21694
- Auberle C, Gao F, Sloan M, Morgensztern D, Winkler L, Ward JP, Devarakonda S, Rearden TP, Govindan R, Waqar SN. A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer. J Thorac Dis. 2024 Jun 30;16(6):3782-3793. doi: 10.21037/jtd-23-1717. Epub 2024 Jun 12.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nintedanib | Small molecule | 200 mg | Oral |